There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics (SGEN), Bristol Myers (BMY) and BioMarin Pharmaceutical Inc. (BMRN) with bullish sentiments.
Seattle Genetics (SGEN)
William Blair analyst Andy Hsieh reiterated a Buy rating on Seattle Genetics on October 21. The company’s shares closed last Monday at $101.01, close to its 52-week high of $102.84.
According to TipRanks.com, Hsieh is a 3-star analyst with an average return of 4.3% and a 44.0% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Nektar Therapeutics, and Pfenex.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seattle Genetics with a $103.92 average price target, implying a 4.6% upside from current levels. In a report issued on October 21, Needham also maintained a Buy rating on the stock with a $121.00 price target.
See today’s analyst top recommended stocks >>
Bristol Myers (BMY)
William Blair analyst Matt Phipps maintained a Buy rating on Bristol Myers on October 22. The company’s shares closed last Monday at $55.04, close to its 52-week high of $57.37.
According to TipRanks.com, Phipps has 0 stars on 0-5 star ranking scale with an average return of -18.1% and a 35.9% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Autolus Therapeutics Plc, and Kezar Life Sciences Inc.
Currently, the analyst consensus on Bristol Myers is a Strong Buy with an average price target of $65.00, representing a 19.3% upside. In a report issued on October 16, Merrill Lynch also resumed coverage with a Buy rating on the stock with a $60.00 price target.
BioMarin Pharmaceutical Inc. (BMRN)
William Blair analyst Tim Lugo maintained a Buy rating on BioMarin Pharmaceutical Inc. on October 23. The company’s shares closed last Monday at $71.20.
According to TipRanks.com, Lugo is a 4-star analyst with an average return of 5.6% and a 38.7% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Collegium Pharmaceutical, and Aclaris Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical Inc. with a $113.92 average price target, implying a 63.8% upside from current levels. In a report issued on October 16, Merrill Lynch also initiated coverage with a Buy rating on the stock with a $90.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
